Printer Friendly

3TC PROCEEDS TO PHASE II/III CLINICAL TRIALS

 LAVAL, Quebec, March 23 /PRNewswire/ -- BioChem Pharma Inc. (NASDAQ: BCHXF) ("BioChem") announced today that several Phase II/III clinical trials of 3TC will begin shortly in patients infected with HIV. In the United States the tests will be conducted under an Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration. Similar applications have been made in other countries.
 These multicentre surrogate markers trials will compare 3TC, alone and in combination with AZT, to AZT or to AZT plus ddC, in early and advanced HIV infection.
 Glaxo is managing the development of 3TC as part of a collaborative agreement with BioChem that also covers commercialization of the drug.
 BioChem Pharma is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. The company's shares are traded on the Montreal and Toronto stock exchanges (BCH) and on the NASDAQ stock market (BCHXF).
 -0- 3/23/93
 /CONTACT: Jean-Yves Duthel, vice president-public relations, BioChem Pharma Inc., 514-681-1744/
 (BCHXF)


CO: BioChem Pharma Inc. ST: Quebec IN: MCT SU: PDT

LD -- NY009 -- 8497 03/23/93 08:18 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1993
Words:191
Previous Article:AMERICAN MEDICAL RESPONSE ANNOUNCES ACQUISITION; NATION'S LEADING PROVIDER OF AMBULANCE SERVICES; MAKES SECOND COLORADO ACQUISITION --
Next Article:FORD, GE FIRST TO TEST NEW RECYCLING PROGRAM
Topics:


Related Articles
PRESENTATION OF PRELIMINARY DATA ON 3TC IN THE TREATMENT OF HIV INFECTION AT THE INTERNATIONAL CONFERENCE ON AIDS IN AMSTERDAM
3TC RESULTS TO BE SUBMITTED TO REGULATORY AUTHORITIES TO PROCEED TO DEFINITIVE PHASE OF TRIALS
3TC PROCEEDS TO PHASE II/III CLINICAL TRIALS
AIDS Clinical Trial Group (ACTG) To Conduct Clinical Study of 141W94/VX-478, an HIV Protease Inhibitor
Phase III Pivotal Clinical Trial Begins with 141W94/VX-478, a Protease Inhibitor Designed by Vertex for Treatment of HIV Infection and AIDS
Vertex and Glaxo Wellcome Announce Pivotal Phase III Trial of HIV Protease Inhibitor 141W94 (VX-478) in Pediatric Patients
Vertex and Glaxo Wellcome Begin Third Phase III Pivotal Trial with HIV Protease Inhibitor 141W94 (VX-478)
Vertex Pharmaceuticals Reports Encouraging Preliminary Data from Phase II Clinical Study with HIV Protease Inhibitor 141W94
Hemispherx Expands Phase III CFS Trial; 4th Center Contracts to Enroll Ampligen(R) Patients.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters